Close the divestiture of the BTG Specialty Pharmaceuticals business
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Dec 2020
- Due
- 30 Jun 2021
- Delivered
- 1 Mar 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is expected to close in the first half of 2021, subject to customary regulatory approvals and other closing conditions.”
What we found
Evidence strength A What the grades mean
Later 10-Q and 10-K filings state the Specialty Pharmaceuticals divestiture closed on March 1, 2021, before the June 30, 2021 deadline.
-
A Boston Scientific 10-Q filed 2021-11-04
“On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, for a purchase price of approximately $800 million” ✓ confirmed on the page
-
A Boston Scientific 10-K filed 2022-02-23
“On March 1, 2021, we completed the divestiture for a purchase price of approximately $800 million, which was subject to certain adjustments including cash on hand at the closing of the transaction.” ✓ confirmed on the page
Market reaction: the shares moved +0.1% against the S&P 500 over the three sessions around the disclosure (3 Nov 2021 to 8 Nov 2021). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- BTG Specialty Pharmaceuticals business divestiture
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to customary regulatory approvals; other closing conditions
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Boston Scientific? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-BSX-005383 · Corrections policy